<DOC>
	<DOCNO>NCT02534909</DOCNO>
	<brief_summary>To determine whether LFG316 induce hematological response , measure reduction hemolytic activity , patient PNH .</brief_summary>
	<brief_title>Proof Concept Study Assess Efficacy , Safety Pharmacokinetics LFG316 Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Male female patient age 1875 ( inclusive ) , 1865 ( applicable Czech Republic ) diagnosis PNH prior screen A documented PNH clone size â‰¥10 % RBCs and/or granulocyte Serum LDH level least 1.5fold upper limit normal ( ULN ) screen Negative pregnancy test woman child bear potential screen Previous vaccination Neisseria meningitidis require least 2 week prior first dose . Known suspected hereditary complement deficiency History recurrent meningitis , history meningococcal meningitis despite vaccination Presence suspicion ( base judgment investigator ) active bacterial infection within 2 week prior first dose LFG316 , recurrent bacterial infection Under active therapy agent interfere complement system Severe concurrent comorbidities likely cause underlying autoimmune disease PNH Women childbearing potential , unless use highly effective method contraception dose 50 day last dose LFG316 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PNH</keyword>
</DOC>